Category Archives: Embryonic Stem Cells


Merck KGaA opens Shanghai Innovation Center and invests $ 14 million in the China Seed Fund – asume tech

Advertisement

One of the largest German pharmaceutical companies sets up a seed capital fund to promote start-ups in China.

Darmstadt-based Merck KGaA announced on Friday that it had a seed capital fund worth 100 million Chinese yuan, or 14.1 million dollars, under the umbrella of its $ 334.2 million venture capital arm M Ventures has set up. Merck KGaA operates in the United States under the name of EMD Serono to avoid confusion with New Jersey-based Whitehouse Station Merck & Co., which trades outside of North America under the name of MSD.

In addition to founding the Seed Fund, Merck KGaA has opened an Innovation Center in Shanghai and is planning another one in the southern metropolis of Guangzhou, which will open next month.

"Our 100 million RMB China Seed Fund underlines our commitment to invest in the Chinese market," said CEO Stefan Oschmann at the opening of the Shanghai Center, citing the abbreviation for Renminbi, the official name of the Chinese currency. "Our innovation centers in China will accelerate our innovation development across the country."

Biotechnology and pharmaceuticals are top priorities in the Chinese government's industrial development strategy. Numerous drug manufacturers operate in the country and are expanding abroad to Western countries.

In January, Beijing-based BeiGene of the Food and Drug Administration received groundbreaking approval for the treatment of zanubrutinib, a Bruton tyrosine kinase inhibitor, which is being developed for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia. ibrutinib) and AstraZeneca's Calquence (acalabrutinib). The company partnered with Summit, Celgene, New Jersey, to develop its PD-1 inhibitor tislelizumab, although the company regained rights to the drug in June, as Celgene acquired the company from Bristol-Myers Squibb, that has its own PD-1 inhibitor, opdivo (nivolumab).

Merck KGaA announced that its Shanghai hub, which was founded last year, will occupy a place in the city's New Bund World Trade Center. Partnerships have already been established, not only in the areas the company specializes in, but also in the areas of artificial intelligence for health solutions. To date, six startups from China and other Asian countries have participated in its Accelerator program.

Photo: VCG, Getty Images

(tagsToTranslate) Weight Loss (t) Obesity (t) Overweight (t) Diabetes (t) Massachusetts (t) Medical Devices (t) Obesity (t) Start-ups (t) Healthcare Innovation (t) Medical News (t) Medical News (t) San Francisco (t) Startups (t) Life Sciences (t) Accelerator (r) Rock Health (t) Startup Consultancy (t) Startup Financing (t) Patient Monitoring System (t) Motion Sensors (t) DC (t) Healthcare it (t) Washington (t) Foodborne Pathogens (t) Diagnostic Companies (t) Diagnostic Platforms (t) Minimally Invasive Surgery (t) Laser Surgery (t) Cambridge (t) Dealflow (t) Hospitals (t) Wellpoint (t) healthways (t) health and wellness (t) employee wellness programs (t) investments (t) wellness (t) medtronic (t) shanghai innovation center (t) china (t) r & d (t) china (t) mdt (t) minneapolis (t) minnesota (t) publics (t) twin cities (t) ulcerative colitis (t) abbott labs (t) humira (t) abbott labs (t) doctors (t) pharmaceuticals (t) skin diseases (t) pharmaceuticals (t) md Anderson cancer center (t) cancer (t) Texas (t) kidney Denervation (t) st. Jude Medical (t) st. electronic medical records (t) electronic health records (t) certified emr (t) certified emr (t) ehr (t) electronic health records (t) electronic medical records (t ) Advanced Cell Technology (t) Amyotrophic Lateral Sclerosis (t) Embryonic Stem Cells (t) Geron Corporation (t) Lou Gehrig

Advertisement

Continued here:
Merck KGaA opens Shanghai Innovation Center and invests $ 14 million in the China Seed Fund - asume tech

Syros sees strategic shift after the failure of the previously promising cancer drug – asume tech

Advertisement

A biotech company developing drugs to treat cancer by controlling gene expression is shifting its focus to the failure of a drug that has been tested in patients with solid tumors.

Syros of Cambridge, Massachusetts, said Thursday that data from the extension of his phase I trial of SY-1365, an intravenous CDK7 inhibitor, did not show that a patient had achieved an objective response to treatment. The best response was a stable disease in 13 out of 31 patients whose efficacy could be assessed, meaning that their tumors did not continue to grow, but did not contract. The study enrolled patients with breast cancer, ovarian cancer and advanced solid tumors enrolled in single drug and combination cohorts.

The shares of Syros gave after the news against the Nasdaq by 32.3 percent.

The company has therefore decided to shift its focus from SY-1365 to another drug, the oral CDK7 inhibitor SY-5609, which more selectively and effectively inhibits CDK7 than SY-1365, and has shown stronger antitumor activity in preclinical tests. The Company plans to discontinue the development of SY-1365 and initiate a Phase I trial of SY-5609 in the first quarter of 2020.

Patients in the single drug expansion cohorts received SY-1365 initially twice weekly at 80 mg per square meter of body area, while patients in the combination cohorts received it once weekly at 53 mg per square meter. Adverse reactions believed to be related to intravenous administration including headache, nausea and vomiting prompted the company to investigate extended cohort infusion times and lower doses in the single-agent cohorts.

However, Syros believes that more frequent dosing or a higher dose, which would prolong the infusion time to improve the tolerability of the drug, would be needed to maintain the CDK7 targeting required for sufficient clinical activity both would be the case to a dosing schedule that is overly stressful for patients. SY-5609 can solve this dilemma better, the company said.

The lack of objective answers in the study suggests that dose reductions and longer infusion times could affect efficacy, Cowen analyst Phil Nadeau said in a statement to investors on Thursday. The news was disappointing as the preclinical data and Phase I dose-response data suggested that SY-1365 would be more effective and safer.

Photo: Jane1, Getty Images

(tagsToTranslate) Weight Loss (t) Obesity (t) Overweight (t) Diabetes (t) Massachusetts (t) Medical Devices (t) Obesity (t) Start-ups (t) Healthcare Innovation (t) Medical News (t) Medical News (t) San Francisco (t) Startups (t) Life Sciences (t) Accelerator (r) Rock Health (t) Startup Consultancy (t) Startup Financing (t) Patient Monitoring System (t) Motion Sensors (t) DC (t) Healthcare it (t) Washington (t) Foodborne Pathogens (t) Diagnostic Companies (t) Diagnostic Platforms (t) Minimally Invasive Surgery (t) Laser Surgery (t) Cambridge (t) Dealflow (t) Hospitals (t) Wellpoint (t) healthways (t) health and wellness (t) employee wellness programs (t) investments (t) wellness (t) medtronic (t) shanghai innovation center (t) china (t) r & d (t) china (t) mdt (t) minneapolis (t) minnesota (t) publics (t) twin cities (t) ulcerative colitis (t) abbott labs (t) humira (t) abbott labs (t) doctors (t) pharmaceuticals (t) skin diseases (t) pharmaceuticals (t) md Anderson cancer center (t) cancer (t) Texas (t) kidney Denervation (t) st. Jude Medical (t) st. electronic medical records (t) electronic health records (t) certified emr (t) certified emr (t) ehr (t) electronic health records (t) electronic medical records (t ) Advanced Cell Technology (t) Amyotrophic Lateral Sclerosis (t) Embryonic Stem Cells (t) Geron Corporation (t) Lou Gehrig

Advertisement

See the original post here:
Syros sees strategic shift after the failure of the previously promising cancer drug - asume tech

Health policy will be the focus of the HLTH – asume tech

Advertisement

In the second year HLTH Conference From 27 to 30 October at the MGM Grand in Las Vegas, health policy will be the focus of a series of discussions discussing fundamental health challenges. Discussions include the drug pricing debate, which balances regulatory needs for health technology with drug development and innovation. and the proper role of the government in health care.

On the morning of October 29th Dr. Amy AbernethyThe Deputy Chief Commissioner of the FDA will explain her view on technology, innovation, the medical ecosystem, and how this fits in with the regulatory approach of the FDA. Later that day, he was CEO of US International Development Financial Corp. Adam Boehler teamed up with the A Healthy Dose Podcast by Stephen Kraus, a health partner of Bessemer Venture Partners and Trevor PriceFounder and CEO of Oxeon Partners to provide insights into entrepreneurship, investment, government policy, Medicaid & Medicare and more.

On Wednesday, October 30, Deputy Secretary of Health and Human Services Eric Hargan discusses value-based care initiatives. Joe Grogan, Director of the National Policy Council, will give an insight into the Trump Administration's mission to give Americans more options and more control over their health. senator Michael Bennet, a presidential candidate will work out his plan for universal health insurance.

Deputy Chairman of the Council of Economic Advisers Tomas Philipson and Centers for Medicare and Medicaid Administrator Seema Verma Philipson will address the role of the government in two separate talks on Sunday, October 28. Philipson will focus on pricing for prescription drugs and the role of government policy in improving patient access to medicines and reducing healthcare costs. Verma will talk about what role the government can play in combating dissatisfaction with the current health care system.

For the first time ever, MedCity News and HLTH have teamed to unveil MedCity's annual ENGAGE patient engagement event at the HLTH conference on October 28. ENGAGE at HLTH will examine how technology, vendors, and payers affect the patient experience and, most importantly, the patient's perspective on healthcare.

Photo: Bill Oxford, Getty Images

(tagsToTranslate) Weight Loss (t) Obesity (t) Overweight (t) Diabetes (t) Massachusetts (t) Medical Devices (t) Obesity (t) Start-ups (t) Healthcare Innovation (t) Medical News (t) Medical News (t) San Francisco (t) Startups (t) Life Sciences (t) Accelerator (r) Rock Health (t) Startup Consultancy (t) Startup Financing (t) Patient Monitoring System (t) Motion Sensors (t) DC (t) Healthcare it (t) Washington (t) Foodborne Pathogens (t) Diagnostic Companies (t) Diagnostic Platforms (t) Minimally Invasive Surgery (t) Laser Surgery (t) Cambridge (t) Dealflow (t) Hospitals (t) Wellpoint (t) healthways (t) health and wellness (t) employee wellness programs (t) investments (t) wellness (t) medtronic (t) shanghai innovation center (t) china (t) r & d (t) china (t) mdt (t) minneapolis (t) minnesota (t) publics (t) twin cities (t) ulcerative colitis (t) abbott labs (t) humira (t) abbott labs (t) doctors (t) pharmaceuticals (t) skin diseases (t) pharmaceuticals (t) md Anderson cancer center (t) cancer (t) Texas (t) kidney Denervation (t) st. Jude Medical (t) st. electronic medical records (t) electronic health records (t) certified emr (t) certified emr (t) ehr (t) electronic health records (t) electronic medical records (t ) Advanced Cell Technology (t) Amyotrophic Lateral Sclerosis (t) Embryonic Stem Cells (t) Geron Corporation (t) Lou Gehrig

Advertisement

Continue reading here:
Health policy will be the focus of the HLTH - asume tech

What Theranos Whistleblowers Learn About Ethics in Health Startups – asume tech

Advertisement

Erika Cheung and Tyler Shultz were the whistleblowers who helped expose the corruption in Theranos. They spoke at the Manova Summit in Minneapolis this week.

The Whistleblowers of Theranos, Erika Cheung and Tyler Shultz, shared some lessons from working in a culture of fear and secrecy at the Manova Global Summit on the Future of Health in Minneapolis.

"There were words we could not say at Theranos, like 'biology', 'pipette', 'research'," "recalled Shultz." And we should not talk to other people at Theranos about what you did. "

Even so, the two had no other career experience, so it took awhile for the red flags to add up, Cheung said.

Now that the former Theranos leadership is waiting for a test in 2020, Cheung and Shultz have formed an organization they call Ethics in Entrepreneurship, hoping to prevent other technology and health startups and associates from doing so do what they did.

"We're all here because we want to make a difference and we want to do good and we have good intentions, but making sure you have that strong vision and figuring out how to sustain that is a challenge," Cheung said. "You have to figure out how to stick to these morals, standards and values despite the chaos."

Although they do not yet have all the answers at the moment, they pointed to some basics that can be applied to just about any business:

In Silicon Valley, so-called vanity boards are popular, Cheung agreed, but just in a heavily regulated area like healthcare, "you need the right people to ask the right questions."

Although Shultz spent most of his 20s in the Theranos scandal, he remains optimistic.

"So many things have gone wrong (in the case of Theranos) that I think it's unlikely to happen again," he said. "Although I may be naive."

Abbe's presenter Rebecca Jarvis asked the two of them if they felt Theranos's former director, Elizabeth Holmes, was going to jail.

"There has to be some justice," Cheung said to the audience with great applause. "It must."

Photo: Andrew McGee, Manova

(tagsToTranslate) Weight Loss (t) Obesity (t) Overweight (t) Diabetes (t) Massachusetts (t) Medical Devices (t) Obesity (t) Start-ups (t) Healthcare Innovation (t) Medical News (t) Medical News (t) San Francisco (t) Startups (t) Life Sciences (t) Accelerator (r) Rock Health (t) Startup Consultancy (t) Startup Financing (t) Patient Monitoring System (t) Motion Sensors (t) DC (t) Healthcare it (t) Washington (t) Foodborne Pathogens (t) Diagnostic Companies (t) Diagnostic Platforms (t) Minimally Invasive Surgery (t) Laser Surgery (t) Cambridge (t) Dealflow (t) Hospitals (t) Wellpoint (t) healthways (t) health and wellness (t) employee wellness programs (t) investments (t) wellness (t) medtronic (t) shanghai innovation center (t) china (t) r & d (t) china (t) mdt (t) minneapolis (t) minnesota (t) publics (t) twin cities (t) ulcerative colitis (t) abbott labs (t) humira (t) abbott labs (t) doctors (t) pharmaceuticals (t) skin diseases (t) pharmaceuticals (t) md Anderson cancer center (t) cancer (t) Texas (t) kidney Denervation (t) st. Jude Medical (t) st. electronic medical records (t) electronic health records (t) certified emr (t) certified emr (t) ehr (t) electronic health records (t) electronic medical records (t ) Advanced Cell Technology (t) Amyotrophic Lateral Sclerosis (t) Embryonic Stem Cells (t) Geron Corporation (t) Lou Gehrig

Advertisement

See the original post:
What Theranos Whistleblowers Learn About Ethics in Health Startups - asume tech

Assessments of Treatment Options for Age-related Macular Degeneration – DocWire News

Several papers presented at AAO 2019 discussed different outcomes for treatments of age-related macular degeneration (AMD).

The first paper, Phase 1 Single and Multiple Ascending Dose Studies of LBS-008, a Novel Therapy for Stargardt Disease and Dry AMD, is the first human study to evaluate safety, pharmacokinetics (PK), and pharmacodynamics (PD) of oral LBS-008, according to the researchers. The study included 40 patients in five cohorts for the single ascending dose (SAD) arm, and 32 patients in four cohorts for the multiple ascending dose (MAD) arm. In each cohort, six patients received LBS-008 and two received placebo. The SAD doses were 25 mg, 50 mg, 100 mg, 200 mg, and 400 mg, and the MAD doses were 10 mg, 25 mg, 50 mg, and 100 mg, for 14 days. Outcomes included serum RBP4 and retinol levels. LBS-008 use resulted in good safety, PK, and PD outcomes; no dose-limiting toxicities occurred in patients who completed the trial, and RBP4 lowering reached 90%.

The second paper, Phase 1/2a Study of Subretinally Transplanted Human Embryonic Stem Cell-Derived RPE Cells in Advanced Dry-Form AMD Patients, reported interim data on patients partaking in the Phase I/IIa Dose Escalation Safety and Efficacy Study of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelium Cells Transplanted Subretinally in Patients With Advanced Dry-Form Age-Related Macular Degeneration (Geographic Atrophy) clinical trial. In this study, patients with advanced dry AMD (n = 15) underwent transplant to receive human embryonic stem cell-derived retinal pigment epithelial cells (OpRegen). Two routes of administration were used: pars plana vitrectomy or injection via the suprachoroidal route. Functional/structural outcomes were evaluated with best corrected visual acuity (BCVA) and imaging. The researchers reported positive interim outcomes and no unexpected adverse events (AEs). OpRegen was associated with subretinal pigmentation, decreased drusen density, irregular reflectance above atrophy areas, and ellipsoid zone changes as evidenced through optical coherence tomography imaging.

The third paper, Ziv-Aflibercept Efficacy in Better Regulating AMD: 52-Week Results of the ZEBRA Study, compared ziv-aflibercept to other antivascular endothelial growth factor (anti-VEGF) agents in neovascular AMD patients. Eligible patients were required to have active disease, a history of anti-VEGF treatment, and BCVA < 20/250. Patients were randomized to two groups: one group received 1.25 mg/0.05mL intravitreal ziv-aflibercept (treatment group), and the other continued their current treatment plan (control group). Final analysis included 56 patients. Mean baseline BCVA at one year was 1.58 0.42 logMAR in the control group and 1.76 0.32 logMAR in the treatment arm; mean changes in BCVA were 0.07 and 0.01 logMAR, respectively. Baseline central foveal thickness (CFT) was 261 81 m in the control group and 242 79 m in the treatment group; mean changes in CFT were 7 and 3 m, respectively. No AEs occurred in either group. The authors concluded that ziv-aflibercept is anatomically and functionally noninferior to other anti-VEGF agents and may be a cost-effective option compared to aflibercept and could serve as a second-line therapy for eyes that do not respond to bevacizumab.

See the original post:
Assessments of Treatment Options for Age-related Macular Degeneration - DocWire News

Stem Cells Market Growth Rate, Production Volume and Future Opportunities From 2019-2024 – Exponent Online

The report Global and Regional Stem Cells Industry Production, Sales and Consumption Status and Prospects Professional Market Research Report 2019-2024 provides an in-depth analysis of global Stem Cells market across top key players, products and Applications. The Stem Cells report provides comprehensive coverage on major industry drivers, restraints, and their impact on market growth during the forecast period.

Analyst projects that the Stem Cells market size will grow from XX Million USD in 2018 to XX Million USD by 2024, at an estimated CAGR of XX%. The base year considered for the study is 2018, and the market size is projected from 2019 to 2024.

Osiris Therapeutics, Inc., Cytori Therapeutics, Inc., BrainStorm Cell Therapeutics Inc., U.S. Stem Cell, Inc., Takara Bio Inc., BioTime Inc., Cellular Engineering Technologies Inc., Astellas Pharma Inc., Caladrius Biosciences, Inc., STEMCELL Technologies Inc.

By ProductAdult Stem Cell, Human Embryonic Stem Cell, Induced Pluripotent Stem Cell

By SourceAutologous, Allogeneic,

By ApplicationRegenerative Medicine, Drug Discovery and Development,

By End UserTherapeutic Companies, Cell and Tissue Banks, Tools and Reagent Companies, Service Companies,

By

By

Request For Sample Report at https://www.proaxivereports.com/request-sample/7503

Market outlook for Stem Cells market overall as well as across various sub-segments has been provided for the period 2019-25.

Regional analysis is done across major markets as following:

United StatesEuropeChinaJapanIndia

The growth factors of the Stem Cells market is discussed in detail wherein the different end users of the market are explained in detail.

The report contains the SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.

Ask for special discount on Stem Cells Market report at https://www.proaxivereports.com/discount/7503

The points that are discussed within the report are the major market players that are involved in the market such as manufacturers, raw material suppliers, equipment suppliers, end users, traders, distributors and etc.

The complete profile of the major companies of Stem Cells industry is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. The historical data from 2012 to 2017 and forecast data from 2018 to 2023.

Data and information by manufacturer, by region, by type, by application and etc, and custom research can be added according to specific requirements.

Ask more details or request custom reports to our experts at https://www.proaxivereports.com/pre-order/7503

Key Reasons to Purchase this report

To gain insightful analyses of the Stem Cells market and have comprehensive understanding of the global market and its commercial landscape.

Assess the production processes, major issues, and solutions to mitigate the development risk.

To understand the most affecting driving and restraining forces in the market and its impact in the global market.

Learn about the Stem Cells market strategies that are being adopted by leading respective organizations.

To understand the outlook and prospects for the market.

Besides the standard structure reports, we also provide custom research according to specific requirements.

Purchase Stem Cells Market Report at https://www.proaxivereports.com/checkout/7503

Post Views: 17

Read the original post:
Stem Cells Market Growth Rate, Production Volume and Future Opportunities From 2019-2024 - Exponent Online

Catholics more motivated to donate if ethical investing is assured – Crux: Covering all things Catholic

WASHINGTON, D.C. Nearly nine in 10 Catholics surveyed said they want their donations to church institutions to be ethically invested and a majority of those responding voiced particular opposition to investments in companies that produce pornography, tobacco products and e-cigarettes, according to a new survey.

The survey for Boston-based Catholic Investment Services found that about 87 percent of respondents would be more likely to donate to Catholic institutions if they knew the money would be invested in ways consistent with church teaching and values.

In contrast, about 14 percent of respondents said ethical investing was not a consideration when donating to Catholic institutions.

The results parallel those of a CIS survey released in April. Peter Jeton, the firms outgoing CEO, said the new study sought to more specifically identify what investments motivate or deter Catholics to give to church entities.

People want their donations to go where its good and avoid evil, Jeton said.

Ethical investing can be a motivating factor in how much people give, he told Catholic News Service. And if I am the CFO (chief financial officer) of a diocese or if Im the bishop of a diocese, then I should be explaining very clearly and with frequency what the policy is regarding how peoples money is being invested.

The survey involved 500 Catholic adults who answered a series of online questions Sept. 7-9. It has a margin of error of plus or minus 4.5 percentage points.

It covered more than a dozen types of businesses from manufacturers of medications used during an abortion procedure to oil and natural gas mining to which respondents voiced objections.

In the case of the pornography industry, 60% of respondents said church money should not be invested in such endeavors. Opposition also was raised to investing in tobacco products and e-cigarettes (57 percent), alcoholic beverages (52 percent), medications used during an abortion (52 percent), casinos and gaming (51 percent), medical facilities where abortions occur (50 percent), gun manufacturing (47 percent), for-profit prisons/detention centers (45 percent), security, defense and large-scale weapons (44 percent), research on embryonic stem cells (37 percent), manufacturers of birth control (31 percent) and oil and natural gas extraction (30 percent).

Jeton suggested that institutional financial officers and bishops be fully transparent about their investment decisions. The better the engagement, the better for the Church, he said.

They should emphasize the link with Catholic social teaching, he added. Because if our data is correct, then making people in the pews aware of that should, by all rights, increase the comfort level with the Church and a greater willingness to share more of their financial resources with the Church.

The survey also asked participants what investments Catholic institutions should be making. Among those cited by respondents were clean air and water (67 percent), workforce education/job training (66 percent), education technology (65 percent), agriculture and food (65 percent), health care providers (62 percent), affordable housing (60 percent), recycling (57 percent), renewable energy (53 percent), land conservation (50 percent), fitness/nutrition (49 percent) and banking and financial services to low-income people and small businesses (46 percent).

Catholic Investment Services was founded in 2013 to serve Catholic entities, including dioceses, colleges and universities, hospital systems and social service agencies. Jeton said the firm follows the socially responsible investment guidelines adopted by the U.S. Conference of Catholic Bishops.

Those guidelines, in place since 2003, are divided into six broad categories: protecting human life, promoting human dignity, reducing arms production, pursuing economic justice, protecting the environment and encouraging corporate responsibility. Each category lists specific areas of concern, such as abortion, racial discrimination, labor standards and other social needs in which the Church has had a voice.

Jeton said he hoped the data developed would influence how diocesan bishops in particular discuss finances with the folks in the pew.

They would do well to pay attention to mechanisms that would get more people engaged, Jeton said. Hopefully with greater engagement there is growing willingness (among donors) to go into their back pocket to help the Church.

Crux is dedicated to smart, wired and independent reporting on the Vatican and worldwide Catholic Church. That kind of reporting doesnt come cheap, and we need your support. You can help Crux by giving a small amount monthly, or with a onetime gift. Please remember, Crux is a for-profit organization, so contributions are not tax-deductible.

The rest is here:
Catholics more motivated to donate if ethical investing is assured - Crux: Covering all things Catholic

Greenwood to step down as CEO of BIO after 2020 election – FierceBiotech

Jim Greenwood is set to step down as CEO of the Biotechnology Innovation Organization (BIO) after the 2020 election. Greenwood has held the position for more than half of BIOs history but will now make way for a new leader who will work to defend innovation from domestic political attacks.

Under Greenwoods leadership, BIO tripled in size, growing from a relatively small player in 2005 to a 176-employee organization with an $85 million operating budget. BIO has almost doubled its annual outlay on lobbying under Greenwood, going from spending a little more than $5 million in 2004 to just shy of $10 million last year, according to data tracked by the Center for Responsive Politics.

The increase in spending has covered a period in which BIO has fought to protect drug developers from the perceived threats of government actions. Those threats are arguably as acute today as at any point during Greenwoods reign, and the CEO plans to go out fighting.

CIOs Perspectives: Driving Clinical Trial Innovation with a Unified Platform

IT is being challenged with either trying to fix and maintain an already complex system of solution integrations, or exploring driving business impact by unifying its systems under one platform. Attend and learn about the IT benefits to shifting resources away from disparate systems and moving towards a unified platform.

I will continue my full-throated advocacy to ensure our elected officials do not kill innovation in a populist furor and prevent our scientists from delivering a new generation of genomic cures, Greenwood said in a statement.

The timing of Greenwoods departure means he will continue to make the case for biotech until the end of this election cycle and help support the transition to a new BIO leader in 2021.

Greenwood took over as leader of BIO from its founding president Carl Feldbaum in 2005. Before joining BIO, Greenwood spent 12 years as a Republican member of the House of Representatives. BIO lists efforts to modernize the FDA and lift a ban on embryonic stem cells among the initiatives Greenwood worked on during his time in Congress.

Since leaving to join BIO, Greenwood has continued to shape legislation, leading the industry side of negotiations about the Prescription Drug User Fee Act and the 21st Century Cures Act. Those negotiations have affected how drugs are developed for the U.S. market.

See more here:
Greenwood to step down as CEO of BIO after 2020 election - FierceBiotech

Epigenetic initiation of the TH17 differentiation program is promoted by Cxxc finger protein 1 – Science Advances

INTRODUCTION

T helper 17 (TH17) cells, a subset of CD4+ T cells, are characterized by the secretion of interleukin-17A (IL-17A), IL-17F, IL-21, IL-22, and the transcription factors (TFs) retinoic acid receptorrelated orphan receptor t (RORt) and ROR (13). RORt and ROR are critical drivers of autoimmune tissue inflammation in human autoimmune diseases (multiple sclerosis), mouse models [experimental autoimmune encephalomyelitis (EAE)], and other autoimmune conditions (4). TH17 cells also maintain mucosal tissue homeostasis and contribute to the host defense against bacterial and fungal infections (2, 5). The activation of naive TH cells in the presence of transforming growth factor1 (TGF-1) and IL-6 leads to the development of TH17 cells (6). Other cytokines such as IL-21, IL-1, and IL-23 are crucial for the expansion, stability, and functional maturation of TH17 cells (4, 6, 7). RORt and ROR are the master regulators of TH17 cells, and other TFs, c-Maf, IRF4 (interferon regulatory factor 4), BATF (basic leucine zipper transcription factor, ATF like), and IkB, are required for the induction of RORt, IL-17, IL-21, and IL-22 in vivo and in vitro (8). IL-6, IL-21, and IL-23 can all activate signal transducers and activators of transcription 3 (STAT3), and the activation of STAT3 is crucial for their effects on TH17 cell differentiation (1). The impairment of STAT3 skews TH17 differentiation toward anti-inflammatory Treg cells, and TAZ [transcriptional coactivator with postsynaptic density 65discs largezonula occludens 1binding (PDZ) motif]/TEAD1 (TEA-ATTS DNAbinding domain 1) regulates reciprocal RORt/Foxp3 expression downstream of STAT3 (9).

Epigenetic mechanisms such as DNA methylation and histone acetylation/methylation have been reported as key players in different T cell subsets (10). In TH1 cells, permissive histone modifications and DNA demethylation in interferon- (IFN-) and Tbx21 could promote IFN- expression and help TH1 lineage differentiation and stability (10, 11). The TH2-specific genes (IL4, IL5, and IL13) are repressed by suppressive histone modifications and DNA methylation in the process of TH1 cell differentiation (12). However, TH2 cells contain activated histone modifications and undergo DNA demethylation at the TH2-specific gene cluster, as well as contain repressive histone modifications and undergo DNA methylation in TH1-specific genes (IFN- and Tbx21) (13). Foxp3, the master TF for Treg cells, was marked with permissive H3K4me3 modification and underwent DNA demethylation at its gene locus, which contributes to the determination and commitment of the Treg cell lineage (14). Similarly, genome-wide epigenetic analysis of TH17 cells uncovered the enrichment of permissive histone modifications such as H3K4me3 and DNA demethylation in the promoters of cytokine and lineage-specific genes such as IL17a, IL17f, IL21, IL23r, and Rorc (15).

CXXC finger protein 1 (Cxxc1), defined as an epigenetic regulator, binds to DNA using its CXXC finger domain and recruits SETD1 to most CpG islands (CGIs) through its Setd1-interacting domain (16, 17). Clouaire et al. (16) showed that Cxxc1 is required for H3K4me3 modification in embryonic stem cell, and Thomson et al. (18) found a concordance of Cxxc1 binding with H3K4me3 and nonmethylated CGIs in mouse brain. Our recent studies also demonstrated that Cxxc1-dependent H3K4me3 plays a critical role in thymocyte development, phagocytosis, and the bactericidal activity of macrophages (19, 20). However, the role of Cxxc1-mediated H3K4 trimethylation and DNA methylation in TH cells remains unclear.

To explore the role of Cxxc1 in TH cell differentiation, we took advantage of T cellspecific Cxxc1 knockout (KO) mice. Here, we demonstrate that Cxxc1-deficient TH17 cells exhibited impaired differentiation and stability, which led to susceptibility to bacterial infection and protected against EAE in vivo. Fluorescence-activated cell sorting (FACS) and RNA sequencing (RNA-seq) analyses identified that Cxxc1 deficiency skews TH17 differentiation toward anti-inflammatory Treg cells both in vivo and in vitro.

Via chromatin immunoprecipitation coupled with high-throughput sequencing (ChIP-seq) analysis, we revealed genome-wide Cxxc1-binding sites in TH17 cells and H3K4me3 modification changes in Cxxc1-deficient TH17 cells compared with the wild-type (WT) control. We found that Cxxc1 bound to IL-6R and other TFs (IRF4 and BATF) by maintaining the appropriate H3K4me3 modification of their promoter regions. Moreover, IL-6R, a direct target of Cxxc1, could partially rescue the differentiation and stability defects seen in Cxxc1-deficient TH17 cells. Cxxc1 thus reciprocally regulates the balance between TH17 and Treg cells by regulating IL-6/STAT3 signaling. This suggests that the Cxxc1-mediated epigenetic program is required for T cell differentiation and TH17-related autoimmune diseases.

To investigate the potential role of Cxxc1 in TH cell function, we generated conditional KO mice by crossing mice with loxP-flanked Cxxc1 alleles to mice with transgenic Cre driven by the distal Lck promoter (dLck-Cre mice), which mediated the deletion of genes on peripheral CD4+ and CD8+ T cells. dLckcreCxxc1fl/fl mice developed normally with no obvious difference in their T cell development in the thymus (fig. S1A). Further analysis of the peripheral T cells showed a decrease in CD8+ T cell numbers, especially in its effector/memory population, while CD4+ T cell numbers and phenotypes were normal (fig. S1, B to D). CellTrace dilution showed little impairment of the CD8+ T cell proliferation capacity of Cxxc1-deficient T cells cultured under T cell receptor (TCR) stimulation, while CD4+ T cells showed no influence of TCR stimulation (fig. S1E).

We then isolated naive CD4+ T cells from dLckcreCxxc1wt/wt and dLckcreCxxc1fl/fl mice and conducted T cell differentiation in vitro. We found that Cxxc1 ablation led to severely defective TH17 differentiation characterized by reduced IL-17A and IL-17F in two TH17 cellpolarizing conditions: (i) TGF-1 and IL-6 and (ii) IL-1, IL-6, and IL-23, while Foxp3 expression increased (Fig. 1, A and B). However, Cxxc1-deficient T cells exhibited no obvious difference in TH1 or TH2 differentiation and a moderate increase in induced T-regulatory cell (iTreg) differentiation (fig. S2, A to C), while the expression levels of Cxxc1 protein were consistent among these T helper subsets and in different stimulation time of TH17 cells (fig. S2, G and H). Furthermore, we also used CD4+ T cells from CreERT2+ Cxxc1fl/fl mice to test Cxxc1 function in an in vitro culture system and found a similar requirement for Cxxc1 in TH17 differentiation in the presence or absence of 4-hydroxytamoxifen treatment (which initiated the access of Cre recombinase to the nucleus and led to the deletion of Cxxc1 in vitro, as shown in fig. S2I) (Fig. 1, C and D) for 4 days, and we observed no obvious difference in TH1, TH2, or iTreg differentiation (fig. S2, D to F).

(A and B) Naive CD4+ T cells (CD4+CD25-CD62LhiCD44lo) from dLckcreCxxc1fl/fl or WT mice were differentiated into TH17 cells with (A) IL-6 and TGF-1 or (B) IL-1, IL-6, and IL-23 for 96 hours and then restimulated for intracellular cytokine staining. One of five to seven experiments is shown. (C and D) Naive CD4+ T cells (CD4+CD25-CD62LhiCD44lo) from ERT2creCxxc1fl/fl mice were differentiated into TH17 cells with (C) IL-6 and TGF-1 or (D) IL-1, IL-6, and IL-23 for 96 hours in the presence or absence of 4-OHT (4-Hydroxytamoxifen) and then restimulated for intracellular cytokine staining. One of five experiments is shown. (E and F) Naive CD4+ T cells from RORtcreCxxc1fl/fl or WT mice were differentiated into TH17 cells with (E) IL-6 and TGF-1 or (F) IL-1, IL-6, and IL-23 for 96 hours and then restimulated for intracellular cytokine staining. One of seven experiments is shown. (G) Intracellular staining of IL-17A in lipoprotein lipase (LPL) CD4+ T cells in the small intestines of RORtcreCxxc1fl/fl and WT mice. One of four experiments is shown. Error bars show the means SD. **P 0.01, ***P 0.001, ****P 0.0001 using the Students t test.

Next, we tested the function of Cxxc1 in TH17 cells by generating RORtcre Cxxc1fl/fl mice. Similar to the dLck-mediated deletion of Cxxc1, RORtcre Cxxc1fl/fl mice developed normally in terms of T cell development in the thymus (fig. S3A) and exhibited decreased CD8+ T cell numbers in the periphery (fig. S3, B and D), while CD4+ T cell numbers were normal (fig. S3, B and C). Then, we isolated naive CD4+ T cells from RORtcreCxxc1wt/wt and RORtcre Cxxc1fl/fl mice and conducted TH17 cell differentiation (TGF-1 and IL-6 or IL-1, IL-6, and IL-23) in vitro. Compared with the dLck-mediated deletion of Cxxc1, T cells in RORtcreCxxc1fl/fl mice differentiated under TH17 cellpolarizing conditions showed much less IL-17A and IL-17F production than Cxxc1-competent RORtcreCxxc1wt/wt cells and markedly increased Foxp3 production (Fig. 1, E and F). This is due to the sufficient deletion of Cxxc1 protein in TH17 cells in the RORtcre system compared with dLckcre system (fig. S2I). Under steady-state conditions, TH17 cells are preferentially located in the lamina propria (LP) of the small intestine (3). We also showed that CD4+ T cells in the LP of RORtcre Cxxc1fl/fl mice showed notably reduced IL-17 production in vivo (Fig. 1G), although we found a little increased frequency of Treg cells in LP and normal frequency of Treg cells in lymph nodes and spleen (fig. S3E).

To characterize IL-17A expression more specifically, we introduced IL-17AeGFP reporter mice into dLckcreCxxc1fl/fl and RORtcre Cxxc1fl/fl backgrounds separately, and the results also confirm defective TH17 differentiation in Cxxc1-deficient cells with enhanced green fluorescent protein expression (fig. S3, F and G). These results indicate that Cxxc1 is essential for TH17 cell differentiation in vitro.

To further evaluate whether defects in TH17 cells caused by Cxxc1 deficiency affect the development of TH17-dependent inflammatory diseases in vivo, we used a TH17-dependent autoimmune disease model, EAE, that mimics the human neuroinflammatory disease multiple sclerosis.

As we found decreased CD8+ T cell numbers in the periphery (fig. S3B), to exclude the effect of CD8+ T cell (21), we sorted naive CD4+ T cells (CD4+CD44loCD62L+) from RORtcreCxxc1fl/fl and RORtcreCxxc1wt/wt mice, transferred these cells into Rag1/ mice, and then monitored them for the induction of EAE. In agreement with the results showing the in vitro defects, transfer of RORtcreCxxc1fl/fl-naive CD4+T cells alleviated EAE, and significantly less mononuclear cell infiltration and demyelination of the spinal cord were observed (Fig. 2, A and B). Within the central nervous system (CNS)infiltrating draining lymph nodes and spleen CD4+ T cell population, the production of IL-17A+ T helper cells was reduced in the hosts that had received RORtcreCxxc1fl/fl cells, whereas the number of Treg cells increased in the CNS-infiltrating CD4+ T cells (Fig. 2, C and D). Cxxc1-deficient splenocytes isolated from myelin oligodendrocyte glycoprotein (MOG)immunized mice showed impaired production of IL-17 but normal production of IFN- upon restimulation with the MOG peptide compared with Cxxc1-sufficient splenocytes (Fig. 2E). We found similar results when the EAE model was induced in the Rag1/ hosts with dLckcreCxxc1fl/fl cells compared with dLckcreCxxc1wt/wt cells (fig. S4, A to C). We can find that Cxxc1 deficiency alleviated symptoms of autoimmunity in dLckcreCxxc1fl/fl (fig. S4, D to G) and RORtcreCxxc1fl/fl (fig. S4, H to K) mice compared with appropriate control mice as well. These data suggested that the Cxxc1-deficient cells were less susceptible to the EAE disease model than Cxxc1-sufficient cells, which was in accordance with the in vitro results showing defective IL-17 expression.

(A) Mean clinical scores for EAE in Rag1/ recipients of RORtcreCxxc1fl/fl (n = 13) or WT (n = 11) naive CD4+ T cells after being immunized with MOG3555, complete Freunds adjuvant (CFA), and pertussis toxin. Data are summed from three independent experiments. (B) Representative histology of the spinal cord of Rag1/ mice after EAE induction (day 25). Hematoxylin and eosin (H&E) staining (left), Luxol fast blue (F&B) staining (right). (C) On day 20 after the induction of EAE in Rag1/ hosts, CD4+ T cells were analyzed from leukocytes isolated from the CNS, draining lymph nodes (dLNs), and spleen and further analyzed for the frequency of IL-17A+ and IFN-+ T cells (left). Summary of CNS IL-17A+CD4+ and IFN-+CD4+ T cells in Rag1/ hosts (right). One representative of three experiments is depicted. (D) The frequency of Foxp3+ cells from CNS-infiltrating lymphocytes in Rag1/ EAE mice was determined at day 20 after immunization (top). Summary of CNS Foxp3+CD4+ cells in Rag1/ hosts (bottom). One representative of three experiments is depicted. (E) Splenocytes were rechallenged with the MOG peptide (0, 5, and 25 g/ml) for 3 days, and then, cytokine production was measured by enzyme-linked immunosorbent assay (ELISA). (F) Body weight changes of Rag1/ recipients of naive CD4+ T cells from RORtcreCxxc1fl/fl (n = 12) or WT (n = 11) mice after oral inoculation with C. rodentium at the indicated time points. Data are summed from three independent experiments. (G) Colon length for Rag1/ recipients of naive CD4+ T cells from RORtcreCxxc1fl/fl or WT mice after oral inoculation with C. rodentium at day 7. Summary of colon lengths in Rag1/ hosts (right). (H) Histological analysis of representative colons from Rag1/ hosts 7 days after inoculation. (Photo credit: Feng Lin, Institute of Immunology, Zhejiang University School of Medicine). (I) C. rodentium colony-forming units (CFUs) in the colon 7 days after inoculation. Data are summed from three independent experiments. (J) FACS analysis of IL-22 expression from isolated LPLs in Rag1/ hosts at day 7 after inoculation. One of five experiments is shown. Error bars show the means SD. *P 0.05, **P 0.01, ***P 0.001 using the Students t test.

IL-22 is produced by leukocytes, particularly TH17 cells, and has a crucial role in host defense against bacterial infections. Ouyang and his team (5) found that IL-22 has a crucial role in the early phase of host defense against Citrobacter rodentium. We sorted naive CD4+ T cells from RORtcreCxxc1fl/fl and RORtcreCxxc1wt/wt mice, transferred these cells into Rag1/ mice, and then inoculated them with C. rodentium. On day 7 after inoculation, mice that had undergone transfer of RORtcreCxxc1fl/fl-naive CD4+ T cells developed a more aggravated infection than mice that had undergone transfer of RORtcreCxxc1wt/wt-naive CD4+ T cells. The mice showed a significantly greater loss of body weight and shorter colon length than the WT mice (Fig. 2, F and G). Histological analysis of colons from C. rodentiuminfected RORtcreCxxc1fl/fl mice showed increased mucosal hyperplasia and submucosal inflammation compared to the RORtcreCxxc1wt/wt mice, suggesting that Cxxc1 deficiency leads to compromised epithelial barrier function (Fig. 2H). In addition, we found that the bacterial burdens in the feces of RORtcreCxxc1fl/fl mice were increased compared to those in the feces of RORtcreCxxc1wt/wt mice (Fig. 2I). Cytokine analysis showed reduced IL-22 production in CD4+ T cells and group 3 innate lymphoid cell (ILC3) from the LP of hosts with Cxxc1-deficient cells transfer (Fig. 2J and fig. S5A), and ILC3s IL-22 production impairment is possibly due to increased Treg cells (fig. S5B) (22). We found that IL-17 production was unaffected, which imply that cytokines other than IL-6 may regulate IL-17 in this model, and we found normal STAT3 phosphorylation by IL-21 stimulation of RORtcreCxxc1fl/fl cells (fig. S5, C and D). In addition, we found similar results when we performed C. rodentium model in RORtcreCxxc1fl/fl mice (fig. S5, E to H). These findings further support the conclusion that Cxxc1 contributes to TH17 differentiation and function in vivo.

To further analyze the genes regulated by Cxxc1, we performed RNA-seq analysis of RORtcreCxxc1fl/fl and RORtcreCxxc1wt/wt TH17 cells generated in vitro in the presence of TGF- and IL-6 for 72 hours. The RNA-seq results showed that Cxxc1-deficient TH17 cells almost completely lost their features and exhibited a Treg celllike expression profile. Key TH17 cellrelated cytokines and transcripts (e.g., Il17a, Il17f, Il21, Il22, Il6ra, Irf4, Cxcr4, Maf, and Satb1) were significantly down-regulated in RORtcreCxxc1fl/fl TH17 cells, and the master TFs Rorc and Rora also showed a decrease in expression (Fig. 3, A and B). Key Treg cellrelated transcripts (e.g., Foxp3, Ccl3, Itgae, Gpr83, Mgat5, Ikzf2, Ikzf4, Tigit, and Tnfsf10) were significantly up-regulated in RORtcreCxxc1fl/fl TH17 cells (Fig. 3, A and B). Using a fold change of 2 and P < 0.05 to threshold parameters, we found that 782 genes were down-regulated by Cxxc1 knockdown in Cxxc1-defcient cells, and 1411 genes were up-regulated. By pathway analysis, we found the significant enrichment of many genes associated with the inflammatory response and immune-related signaling pathways (e.g., the Janus kinaseSTAT cascade and tyrosine phosphorylation of STAT3 protein) (Fig. 3C). We then measured the expression of TH17 and Treg signature genes, including Il17a, Il17f, Il21, Il22, Rorc, Il6ra, Foxp3, Mgat5, Itgae, Gpr83, Tgfbr1, and Ccl3, from Cxxc1-deficient cells and Cxxc1-sufficient cells by quantitative polymerase chain reaction (qPCR) and obtained the same results as those from 72-hour RNA-seq analysis (Fig. 3D). We also verified these genes in dLCK-Creinduced Cxxc1-deficient TH17 cells by qPCR and got the same results (fig. S5I), which indicates that Cxxc1-deficient TH17 cells exhibit a Treg celllike expression profile.

(A) Naive CD4+ T cells (CD4+CD25CD62LhiCD44lo) from WT and RORtcreCxxc1fl/fl mice were differentiated in the presence of TGF-1 and IL-6 (TH17) for 72 hours, and the total RNA from the cells was analyzed by RNA-seq [STAR (structured transparent accessible reporting) method]. Scatter diagram showing changes in gene expression in WT and Cxxc1-deficient TH17 cells. Down-regulated genes are indicated in blue; up-regulated genes are indicated in red. (B) Heatmap of the fold change (log2) for differentially expressed genes (false discovery rate < 0.05 in TH17 cells is shown). (C) Pathway analysis of the down-regulated genes (left) and up-regulated genes (right). (D) The expression of the selected transcripts was quantified in TH17 cell samples differentiated from naive CD4+ T cells with TGF-1 and IL-6 for 72 hours by real-time qPCR. One of five experiments is shown. Error bars show the means SD. *P 0.05, **P 0.01, ***P 0.001 using the Students t test.

Cxxc1 has two main functional domains. One domain is the N-terminal domain, which interacts with unmethylated CpG DNA to mediate its interaction with DNA methyltransferases 1 (DNMT1) and stabilizes the DNMT1 protein to regulate DNA methylation (17, 18, 23). The other is the C-terminal domain, which interacts with the Setd1 H3K4 methyltransferase complex through the Smad interaction domain to regulate histone methylation. An N-terminal fragment of Cxxc1 (residues 1 to 367) and Cxxc1 containing the point mutation C375A retain their interaction with DNMT1, but the Setd1-interacting activity of Cxxc1 is interrupted. While the C-terminal fragment of Cxxc1 (residues 361 to 656) and Cxxc1 containing the point mutation C169A still have Setd1-interacting activity and can methylate H3K4, the DNA binding activity of Cxxc1 is interrupted. To explore which functional domains within Cxxc1 were necessary for its role in TH17 differentiation, we used an in vitro TH17 differentiation system, and different vectors expressing mutated Cxxc1 proteins were overexpressed in Cxxc1-deficient TH17 cells. The overexpression of full-length Cxxc1 notably rescued the TH17 differentiation defects seen in Cxxc1-deficient cells (fig. S6A). The overexpression of the two Cxxc1 fragments (residues 1 to 367 and residues 361 to 656) and Cxxc1 containing two point mutations (C169A and C375A) showed that the C-terminal domain of Cxxc1 (residues 361 to 656, C169A) rather than the N-terminal domain of Cxxc1 (residues 1 to 367, C375A) was able to rescue TH17 differentiation in Cxxc1-deficient TH17 cells (fig. S6, A and B). Similarly, the overexpression of the C-terminal domain of Cxxc1 reduced Foxp3 expression in Cxxc1-deficient TH17 cells, but the overexpression of the N-terminal domain of Cxxc1 did not (fig. S6C). We also checked gene expression changes by real-time PCR, such as TH17 and Treg signature genes, including Il17a, Il17f, Il21, Il22, Rorc, Il6ra, Foxp3, Mgat5, Itgae, Gpr83, Tgfbr1, and Ccl3, further elucidating the role of two CXXC1 functional domains (fig. S6D). These data showed that the Setd1-interacting domain but not the DNA binding domain in Cxxc1 is crucial for TH17 differentiation, indicating that Cxxc1 may function through regulating H3K4me3 rather than through DNA methylation in TH17 cells.

To investigate the direct targets of Cxxc1 in TH17 cells, we performed ChIP-seq to map genome-wide Cxxc1-binding sites in WT TH17 cells, as well as in Cxxc1-deficient TH17 cells serving as a negative control. Compared with Cxxc1-binding sites in the mouse genome, an obvious enrichment of Cxxc1-binding sites was found in gene promoters [5-kb upstream and downstream of the transcription start site (TSS), 25.56% of Cxxc1-binding sites versus 2% of the mouse genome], exons (3.52% versus 2%), introns (32.67% verus 20%), and intergenic regions (38.25% versus 76%) (Fig. 4A). This represented a relatively high degree of enrichment at promoter regions compared with the distribution of Cxxc1-binding sites in the mouse genome. Analysis of the average binding location also showed that Cxxc1 showed high binding activity at TSS (Fig. 4B).

(A) Naive CD4+ T cells (CD4+CD25-CD62LhiCD44lo) from WT and RORtcreCxxc1fl/fl mice were differentiated in the presence of TGF-1 and IL-6 (TH17) for 24 hours, and ChIP-seq analysis was conducted to map genome-wide Cxxc1-binding sites in WT TH17 cells. Distribution of the genetic features across the whole mouse genome (mm10) (left) and the distribution of Cxxc1-binding peaks in TH17 cells (right). (B) Distribution of Cxxc1-binding peaks across extended gene bodies in TH17 cells. The tag density of Cxxc1 binding to gene bodies [between the transcription start site (TSS) and the transcription termination site (TTS)], as well as 3-kb upstream of the TSS and 3-kb downstream of the TTS regions of all RefSeq (mm10) genes, was calculated. (C) Enrichment of Cxxc1-binding peaks on CGIs. The tag density of Cxxc1 binding to CGIs and 5-kb flanking regions was calculated. (D) Overlapped regions between Cxxc1-binding sites, H3K4me3 sites, and RNA-seq down-regulated genes in WT and Cxxc1-deficient TH17 cells. (E) Integrative Genomics Viewer browser view of Cxxc1-binding peaks (red) in WT TH17 cells and H3K4me3 markers (blue) in WT and Cxxc1-deficient TH17 cells. (F) Naive WT CD4+ T cells were sorted and cultured under TH17 differentiation conditions (TGF- and IL-6) for 24 hours, and ChIP-qPCR analysis of Cxxc1 binding at the indicated gene loci was performed. (G) Naive CD4+ T cells from WT and RORtcreCxxc1fl/fl mice were differentiated into TH17 cells in the presence of TGF-1 and IL-6 for 24 hours, and H3K4me3 modifications at the indicated gene loci were detected by ChIP-qPCR. The statistical significance was determined by Students t test. Error bars show the means SD. *P 0.05, **P 0.01.

As shown in Fig. 4C, Cxxc1-binding sites were enriched at the center of CGIs, and about 31% of the Cxxc1-binding sites were found to colocalize with CGIs in TH17 cells (fig. S7A). We found that Cxxc1-dependent H3K4me3 modifications might be indispensable during TH17 differentiation (fig. S6); therefore, we carried out ChIP-seq analysis to map the genome-wide H3K4me3 modifications in TH17 cells. Similar to the locations of Cxxc1-binding sites, peaks indicating H3K4me3 modifications were also found mainly in gene promoters, and a reduction in the number of H3K4me3 peaks was found in Cxxc1-deficient TH17 cells (fig. S7B).

We mapped the genes with direct CXXC1 binding, genes with at least twofold difference of H3K4me3 modifications between WT and CXXC1 KO cells, and genes positively regulated by CXXC1 (at least twofold difference in gene expression between WT and KO cells). As shown in the Venn diagram (Fig. 4D), the loci of 1874 of 2346 (80%) genes with direct CXXC1 binding were associated with H3K4me3 changes, suggesting an important role of CXXC1 in mediating the histone modification of H3K4me3 in TH cells. Our data also identified 165 genes positively regulated by CXXC1 through positively changing the H3K4me3 modifications on their loci directly (Fig. 4D and table S1). On the other hand, we were able to identify more than 4000 genes whose expression was negatively regulated by CXXC1, although, in most of the cases, through indirect signaling pathways without directly affecting the H3K4me3 on their loci (fig. S7C). Together, our data suggest that CXXC1 plays a key role in regulating gene expressions through recruitment of H3K4me3 in TH cells.

ChIP-seq data showed that Cxxc1 bound upstream of or bound to the gene body of the Il6r, Il6st, Runx1, Satb1, Il21, Irf4, Rorc, Rora, and Batf gene loci was associated with a significant decrease in the H3K4me3 modification of the promoter regions of these genes in Cxxc1-deficient TH17 cells (Fig. 4E and fig. S7D). The direct binding of Cxxc1 in WT TH17 cells and the reduction in H3K4me3 modification in Cxxc1-deficient cells at these gene loci were confirmed by ChIP-PCR (Fig. 4, F and G, and fig. S7, E and F).

We then conducted 24-hour RNA-seq to determine potential key genes that are regulated by Cxxc1 at the early stage of differentiation and further confirmed the ChIP-seq results. We found that, even at the early stage, most of the key TH17 cellrelated transcripts (e.g., Il17a, Il17f, Il21, Il22, Il6ra, Il6st, Runx1, and Satb1) were significantly down-regulated in RORtcreCxxc1fl/fl TH17 cells and that the expression of key Treg cellrelated transcripts increased (e.g., Foxp3, Ccl3, Mgat5, Itgae, and Gpr83) (fig. S7G). We measured the expression of those genes by qPCR and obtained the same results as those obtained by 24-hour RNA-seq analysis (fig. S7H). In contrast to the 72-hour RNA-seq and qPCR results, we did not find a remarkable change in Rorc, Rora, or Irf4 expression at 24 hours. Although there are interactions between CXXC1 and loci of Rorc, Rora, and Irf4, these bindings only indicate enhanced accessibility of these loci. It still requires upstream TFs to promote the expression of Rorc, Rora, and IRF4. It may take 24 hours to open the gene locus, while it may take a longer time for essential TFs to promote their expression. Similar to the ChIP-seq results, we found a decline in Il6ra and Il6st (gp130), which organize the functional receptor for IL-6. The IL-6R subunit binds to IL-6 and the IL-6ST subunit, which are involved in signal transduction and play a vital role in TH17 cell differentiation (24).

We found that Il6r showed a significant decline in H3K4me3 modification levels and mRNA expression. Then, we detected the protein levels of IL-6R by flow cytometry and found a significant reduction in IL-6R in Cxxc1-deficient cells under TH17 cellpolarizing conditions (TGF-1 and IL-6) in different stages of differentiation (Fig. 5A). In addition, we found the same phenomenon in pathogenic TH17 cells (IL-1, IL-6, and IL-23), indicating that the reduction of IL-6R is independent of TGF- signaling (Fig. 5B). Moreover, we also detected a significant decline in IL-6R in dLckcre and ERT2cre deletion mice compared with that in WT mice (fig. S8A). Although IL-6ST expression was reduced at 24 hours, we found a moderate increase in IL-6ST expression at 72 hours (fig. S8B). IL-6R may be secreted in its soluble form, sIL-6R, which mediates the response by forming a complex with IL-6ST in a mechanism named trans-signaling (25). We therefore measured the level of sIL-6R in the supernatant by enzyme-linked immunosorbent assay (ELISA) and detected significantly lower levels of sIL-6R in Cxxc1-deficient cells than those in WT mice at all time points under TH17 cellpolarizing conditions (TGF-1 and IL-6) (Fig. 5C). These results indicated that IL-6R expression was significantly reduced in Cxxc1-deficient TH17 cells both in its membrane-bound and soluble forms.

(A and B) Naive CD4+ T cells (CD4+CD25-CD62LhiCD44lo) from RORtcreCxxc1fl/fl and WT mice were differentiated into TH17 cells with IL-6 and TGF-1 (A) or IL-1, IL-6, and IL-23 (B). The expression of IL-6R was measured by flow cytometry (left), and the mean fluorescence intensity (MFI) of IL-6R at different time points was measured (right). One of six experiments is shown. (C) Naive CD4+ T cells from RORtcreCxxc1fl/fl and WT mice were differentiated into TH17 cells with IL-6 and TGF-1, and the supernatants from cell cultures were collected at indicated time points. The amounts of IL-6R were then measured by ELISA. One of four experiments is shown. (D and E) Purified naive CD4+ T cells were stimulated for the indicated times with IL-6 (10 ng/ml). Phosphorylated and total STAT3 proteins were detected by Western blot assays (D) or flow cytometry (E). One of five experiments is shown. (F) Naive CD4+ T cells from WT and RORtcreCxxc1fl/fl mice were polarized into TH17 cells in the presence of TGF- and IL-6, and varying concentrations of IL-6R antibody were added. The expression levels of IL-17A and IL-17F were then analyzed by intracellular staining after 72 hours. One of six experiments is shown. (G and H) Naive CD4+ T cells from WT and RORtcreCxxc1fl/fl mice were cultured in the presence of TGF-1 and varying concentrations of IL-6 for 72 hours, and then, the expression levels of IL-17A, IL-17F, and Foxp3 were analyzed by intracellular staining after restimulation. One of seven experiments is shown. The statistical significance was determined by Students t test. Error bars show the means SD. *P 0.05, **P 0.01, ***P 0.001.

IL-6 signaling is required for the differentiation of TH17 cells, and the activation of STAT3 is a vital component of the TH17 cell induction mechanism (26). The significant reduction of IL-6R in RORtcreCxxc1fl/fl TH17 cells indicated that IL-6 signaling was possibly affected by the loss of Cxxc1 during TH17 differentiation. To assess this, we sorted RORtcreCxxc1wt/wt and RORtcreCxxc1fl/fl naive CD4+ T cells and stimulated them with IL-6 for different time periods, and then, we detected the activation of the downstream signaling protein STAT3. Both Western blot analysis and flow cytometry results showed a significant reduction in STAT3 activation in Cxxc1-deficient cells compared to that in WT cells stimulated with IL-6 (Fig. 5, D and E).

To further confirm the role of IL-6R defects in Cxxc1-deficient TH17 cells, we added different concentrations of IL-6R blocking antibody to TH17 culture medium in vitro. WT TH17 cells showed a marked reduction in differentiation when IL-6R blocking antibody was added, and the higher the concentration of IL-6R blocking antibody was, the lower the level of WT TH17 cell differentiation was. However, there was only a slight impact in Cxxc1-deficient TH17 cells compared with WT cells when IL-6R blocking antibody was added (Fig. 5F), further indicating the defects of IL-6R in Cxxc1-deficient TH17 cells.

IL-6 binds to IL-6R and is required for TH17 differentiation by activating STAT3 and inhibiting TGF-driven Foxp3 expression. The defects in IL-6R expression in TH17 cells may be compensated if the level of IL-6 is increased. To assess this, we polarized naive RORtcreCxxc1wt/wt or RORtcreCxxc1fl/fl CD4+ T cells into TH17 cells with varying levels of IL-6. Although IL-17 expression was only slightly restored with low and moderate levels of IL-6, it was restored with a high level of IL-6 (Fig. 5G). Moreover, IL-6 inhibited Foxp3 expression in RORtcreCxxc1fl/fl cells in a dose-dependent manner (Fig. 5H). These data suggest that Cxxc1 may regulate TH17 differentiation dependent on the IL-6/STAT3 pathway in the modulation of early signaling events downstream of the IL-6 receptor.

IL-21 or IL-6 alone or in combination with TGF- resulted in the up-regulation of the IL-23 receptor (IL-23R), RORt, and the TH17 cytokines. Our flow cytometry results showed no change in IL-21R expression, while the IL-23R expression was decreased in RORtcreCxxc1fl/fl TH17 cells (fig. S8C). The IL-6induced expression of IL-21, a process that is dependent on STAT3 and IL-21, serves as an autocrine factor that promotes and sustains TH17 lineage commitment (1, 7). IL-21, in synergy with TGF-, induced IL-17 expression independent of IL-6 and induced naive IL-6/ T cells into TH17 cells (6, 27). We then cultured naive CD4+ T cells in vitro with varying concentrations of IL-21 along with TGF-. Similar to the results observed upon the addition of varying levels of IL-6, IL-21 restored inconspicuous IL-17A and IL-17F expression at low and moderate levels, while it fully restored IL-17A and IL-17F expression in Cxxc1-deficient cells at high levels (fig. S8D). IL-23 promotes maintenance of the TH17 lineage and maintains the IL-17secreting phenotype, but it does not promote commitment to an IL-17secreting lineage. IL-23 could also induce IL-17A and IL-17F expression independent of IL-6 in conjunction with TGF- in naive CD4+ T cells (6). When naive CD4+ T cells were cultured in vitro with TGF- and varying concentrations of IL-23, defective IL-17A and IL-17F expression could not be restored, even at the highest level of IL-23, in Cxxc1-deficient cells (fig. S8E). In addition, to eliminate the residue effect of IL-6dependent signaling, we added IL-6R blocking antibody in these cultures and found consistent results (fig. S8, F and G).

As TGF- receptors are important for both TH17 and Treg cell differentiation, we detected the expression of TGF- receptors I and II. Protein levels of TGF- receptors I and II detected by flow cytometry analysis did not show a significant change in naive Cxxc1-deficient CD4+ T cells but showed an increase in Cxxc1-deficient TH17 cells compared with WT cells (fig. S9, A and B). Smad3 and Smad2 are downstream of TGF- signaling, and Smad2 positively regulates the generation of TH17 cells (28), while Smad3 promotes iTreg and inhibits TH17 cell differentiation (29). Western blot results showed no significant change in the Smad2 phosphorylation level (fig. S9C), while Smad3 showed a slight increase in phosphorylation (fig. S9D). Furthermore, the TCR activationinduced phosphorylation of both ERK and JNK proteins was also normal in Cxxc1-deficient cells (fig. S9E). These results indicated that Cxxc1-deficient TH17 cells transdifferentiated into Treg cells mainly due to IL-6/STAT3 signaling defects.

To further confirm IL-6R defects in Cxxc1-deficient TH17 cells, we overexpressed IL-6R in Cxxc1-deficient TH17 cells and carried out assays. We infected Cxxc1-deficient TH17 cells with retroviruses IL-6R or Cxxc1 complementary DNA as a positive control. The results showed that the overexpression of IL-6R potently increased the production of IL-17A and IL-17F relative to that in mock-transfected control Cxxc1-deficient TH17 cells (Fig. 6A). In addition, the overexpression of IL-6R could also efficiently reduce Foxp3 expression in Cxxc1-deficient TH17 cells (fig. S9F). Moreover, we found that the overexpression of Cxxc1 and the C-terminal domain of Cxxc1 (residues 361 to 656, C169A) increased the expression of IL-6R compared to that in mock-transfected Cxxc1-deficient TH17 cells, further confirming the regulation of IL-6R by Cxxc1 (Fig. 6B). We also overexpressed IL-6ST in Cxxc1-deficient TH17 cells and did not find the restoration of IL-17A and IL-17F production or the inhibition of Foxp3 expression compared with controls (Fig. 6A and fig. S9F).

(A) Naive CD4+ T cells from WT and RORtcreCxxc1fl/fl mice were differentiated into TH17 cells in the presence of TGF-1 and IL-6, and 20 to 24 hours, later the cells were transfected with the indicated retrovirus (Mock, Cxxc1, IL-6R, and IL-6ST). IL-17A and IL-17F levels were then measured by gated CD4+GFP+ cells after retrovirus infection for 72 hours. One of six experiments is shown. (B) Sorted naive CD4+ T cells were differentiated into TH17 cells in the presence of TGF-1 and IL-6, and 20 to 24 hours later, the cells were transfected with the indicated retrovirus. IL-6R levels were then measured by gated CD4+GFP+ cells after retrovirus infection for 72 hours. One of five experiments is shown. (C) Naive CD4+ T cells from WT and RORtcreCxxc1fl/fl mice were differentiated into TH17 cells in the presence of TGF-1 and IL-6, and 20 to 24 hours later, the cells were transfected with the indicated retrovirus [Mock, STAT3 (WT), STAT3 (A662C, N664C), and STAT3 (Y705A)]. IL-17A and IL-17F levels were then measured by gated CD4+GFP+ cells after retrovirus infection for 72 hours. One of five experiments is shown. (D) Naive CD4+ T cells from WT and RORtcreCxxc1fl/fl mice were differentiated into TH17 cells in the presence of TGF-1 and IL-6, and 20 to 24 hours later, the cells were transfected with the indicated retrovirus. CD4+GFP+ cells were then sorted after retrovirus infection for 72 hours and transferred into RAG1/ hosts. Two days later, the recipient mice were immunized with MOG3555 and FCA plus pertussis toxin to induce EAE. Clinical scores were recorded and calculated each day for the indicated times. Data are summed from three independent experiments. (E) IL-17A and IFN- production by CD4+ T cells isolated from CNS, draining lymph nodes, and spleens of Rag1/ mice at the peak of disease. One representative of three experiments is depicted. Error bars show the means SD. *P 0.05, **P 0.01, ***P 0.001 using the Students t test.

To further determine defects in the activation of STAT3, which is downstream of IL-6, we overexpressed STAT3 in Cxxc1-deficient TH17 cells. Our results showed that the overexpression of the active form of STAT3 (A662C, N664C) (30) strongly increased the production of IL-17A and IL-17F and inhibited Foxp3 expression relative to that in mock-transfected control Cxxc1-deficient TH17 cells, while the overexpression of WT STAT3 and the inactive form of STAT3 had almost no apparent effect (Fig. 6C and fig. S9G). However, we did not detect a change in IL-6R expression when the active form of STAT3 was overexpressed, indicating that IL-6R is upstream of STAT3 (fig. S9H). We also detected the reduced expression of RORt in Cxxc1-deficient TH17 cells, and RORt overexpression in Cxxc1-deficient TH17 cells partially rescued the TH17 differentiation defect under TH0 conditions and TH17-polarizing conditions (fig. S9I). Therefore, defects in STAT3 activation impaired RORt function at the Il17-Il17f locus.

Last, to better understand whether the overexpression of IL-6R in Cxxc1-deficient TH17 cells would affect the development of EAE in vivo, we sorted CD4+GFP+ T cells, transferred them into RAG1/ hosts, and then induced EAE with MOG3555. Mice that received WT TH17 cells developed the most severe disease, and mice that received Cxxc1-deficient TH17 cells overexpressing Cxxc1 or IL-6R developed more severe disease than those that received control Cxxc1-deficient TH17 cells (Fig. 6D). In addition, both the percentage and the number of TH17 cells in the CNS/draining lymph nodes/spleens of Rag1/ mice that received IL-6Roverexpressing TH17 cells were notably higher than those in the control mice (Fig. 6E). These data demonstrated that IL-6R could potently rescue the production of IL-17A in Cxxc1-deficient TH17 cells in vitro and in vivo and that Cxxc1 could restore IL-6R expression in Cxxc1-deficient TH17 cells.

Epigenetic regulation is an essential mechanism to coordinate T cell differentiation. Here, we report a crucial role of Cxxc1, which directly regulates promoter-associated H3K4me3 modification and the expression of genes such as Il6r that are essential for TH17 cell lineage specification. The transition of naive CD4 cells to TH17 cells in Cxxc1-deficient T cells was almost completely blocked, and the cells instead developed a Treg celllike transcriptional profile.

TH17 and Treg lineage differentiation is not only controlled by a combination of their specific cytokine milieus and TFs but also subjected to epigenetic control through various mechanisms. Previous work has shown that histones maintain TH17 cell differentiation and function by inducing histone modifications at the Il17a locus (31). The H3K4me3 methyltransferase MLL/menin/TrxG complex plays a critical role in the regulation of the TH2 cell program in murine and human systems (32). In addition, deletion of the H3K9me2 methyltransferase G9a also produces both TH17 and TH2 cell response defects (33). The conditional deletion of the H3K27me3 demethylases Jmjd3 and tripartite motif-containing 28 has been reported to have an inconsistent effect on the TH17 program, possibly due to different cellular environments (3437). However, our data showed that the loss of Cxxc1 led to a marked CD4+ T cell lineage switch from TH17 cells to Treg cells without affecting TH1 and TH2 cell differentiation. These data suggest that Cxxc1 is essential for TH17 cell differentiation and stability.

The functional receptor for IL-6 is composed of an IL-6R subunit that binds IL-6 and a gp130 subunit involved in signal transduction (38). The binding of IL-6 family of cytokines to their receptors activates STAT3, which is required for TH17 cell differentiation (26, 38). IL-6R is highly expressed in naive T cells and in the early phase of T cell activation, while IL-6R expression decreases in activated T cells. IL-6/gp130/STAT3 signaling is dominant in inhibiting the conversion of conventional T cells into Foxp3+ Treg cells in vivo, and in the absence of IL-6 signaling, almost no other cytokine can inhibit the conversion of T cells to Treg cells effectively (26). Our results showed a significant reduction in the IL-6R protein level in Cxxc1-deficient cells under TH17 cellpolarizing conditions (TGF-1 and IL-6) at different time points. Meanwhile, Cxxc1-deficient TH17 cells exhibited significantly defective TH17 differentiation and the strong expression of Foxp3 both in vitro and in vivo. ChIP-seq analysis revealed that Cxxc1 bound to and enhanced IL-6R by maintaining the appropriate H3K4me3 modification of its promoter regions. The cofactor that is bound by Cxxc1 and specifically enhances IL-6R expression in the early phase of TH17 cell differentiation remains to be elucidated in future studies.

Both the DNA methylation and H3K4me3 domains of Cxxc1 function in different cell types and tissues (1618). However, our overexpression assay indicated that the histone modification of Cxxc1 mostly functions in TH17 cell differentiation and stability. Our ChIP-seq data showed that Cxxc1 bound to TSS or gene body of several key genes involved in TH17 cell differentiation, including the Runx1, Satb1, IL21, Irf4, Rorc, and Rora gene loci, was associated with a significant decrease in the H3K4me3 modification of the promoter regions of these genes in Cxxc1-deficient TH17 cells. Although we suggested that IL-6R was the main target of Cxxc1 in TH17 cell differentiation, there are still some other target genes regulated by Cxxc1 that provide assistance in the TH17 cell differentiation process. In addition, our TH17 data illustrate that the cell typespecific binding profile of Cxxc1 may determine its primary function, which is consistent with our former analysis in thymocyte development and macrophage function.

In summary, we identified Cxxc1 to be a critical positive regulator of TH17 development at the early stage of differentiation, in which it positively regulates autoimmune disease and bactericidal activity mainly through promoting IL-6R expression and the subsequent activation of downstream pathways. Our findings provide insight into the association of epigenetic regulators with TH17 development and supply important clues for therapeutic approaches for the treatment of TH17-related inflammatory and autoimmune diseases.

The Cxxc1fl/fl mouse strain has been described previously (19). The ERT2cre mice were gifts from Y. W. He (Duke University Medical Center). The dLCKcre mice (JAX:012837) and IL-17AeGFP mice (018472 C57BL/6-IL-17atm1Bcgen/J) were from The Jackson Laboratories. The RORtcre mice (JAX: 022791) were gifts from J. Qiu (Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences). Rag1/ mice were purchased from The Jackson Laboratories. All experiments were performed with 6- to 10-week-old mice unless specified. All mice were kept in the Zhejiang University Laboratory Animal Center, and all animal experimental procedures were approved by the Animal Review Committee at Zhejiang University School of Medicine.

To induce EAE in Rag1/ mice, naive CD4+ T cells (CD4+CD25-CD62LhiCD44lo) from WT and RORtcreCxxc1fl/fl or dLckcreCxxc1fl/fl mice were sorted by the Mouse CD4 Nave T cell Enrichment Kit (no. 8804-6824-74, Invitrogen) and intravenously transferred into Rag1/ mice at 2 106 cells per mouse. Two days later, the recipient mice were subjected to EAE induction.

Female age-matched Rag1/ mice (8 to 10 weeks old) were immunized with an emulsion containing the MOG peptide MOG3555 (200 g per mouse; MEVGWYRSPFSRVVHLYRNGK; Sangon) in an equal amount of complete Freunds adjuvant (200 l per mouse; no. 7027, Chondrex Inc.). Pertussis toxin (200 ng per mouse; no. 181, List Biological Laboratories) was administered intravenously 0 and 2 days after induction. Clinical evaluation was performed daily using a five-point scale: 0, no clinical signs; 1, limp tail; 2, paraparesis (weakness, incomplete paralysis of one or two hind limbs); 3, paraplegia (complete paralysis of two hind limbs); 4, hind limb and fore limb paralysis; and 5, moribund or death.

Mice were intracardially perfused with 50 ml of phosphate-buffered saline (PBS). The forebrain and cerebellum were dissected, and spinal cords were collected from the spinal canal. CNS tissue was cut into pieces and digested with collagenase D (2 g/ml; Roche Diagnostics) and deoxyribonuclease I (DNase I; 1 g/ml; Sigma-Aldrich) at 37C for 20 to 30 min while rotating. Mononuclear cells were isolated by passing the tissue through a 200-mesh cell filter membrane, followed by 80%/40% Percoll gradient centrifugation. Mononuclear cells were carefully removed from the interface, washed with PBS, and resuspended in culture medium for further analysis. For cytokine analysis, mononuclear cells were stimulated for 5 hours with phorbol 12-myristate 13-acetate and ionomycin (both from Sigma-Aldrich) in the presence of brefeldin A (eBioscience) and then subjected to flow cytometry analysis to detect intracellular IL-17A, IFN-, and Foxp3.

RAG/ mice were provided with autoclaved water supplemented with antibiotics [ampicillin (1 g/liter), metronidazole (1 g/liter), neomycin (1 g/liter), and vancomycin (0.5 g/liter)] for 6 days and then provided with autoclaved water for 1 day. Then, naive CD4+ T cells (CD4+CD25-CD62LhiCD44lo) from WT and RORtcreCxxc1fl/fl mice were sorted and intravenously transferred into Rag1/ mice at 2 106 cells per mouse. Two days later, the recipient mice were subjected to C. rodentium infection as described (39). Briefly, mice were gavaged with 5 108 C. rodentium cells in 250 l of PBS per mouse. Bacteria were prepared by shaking at 37C overnight in LB broth, and then, the cultures were serially diluted and plated to measure the colony-forming units. Body weight was measured daily. Fecal pellets were collected, weighed, and then homogenized in sterile PBS, and C. rodentium colonies were identified on the basis of morphology after 18 to 24 hours of incubation at 37C on MacConkey agar plates.

To analyze CNS histology, mice were euthanized 22 days after EAE induction, and spinal cords were fixed in 4% paraformaldehyde and embedded in paraffin. Sections were cut and stained with Luxol fast blue and hematoxylin and eosin (H&E). To analyze colon histology, the colons from Rag1/ hosts 7 days after inoculation with C. rodentium were collected, treated as described above, and stained with H&E.

Mouse small intestines were dissected, and fat tissues and Peyers patches were removed. The intestines were cut open longitudinally and washed with Dulbeccos modified Eagles medium (DMEM) until no fecal pellets were observed. The intestines were then cut into approximately 5-mm-long pieces. The intestinal pieces were incubated in 37C prewarmed DMEM containing 3% fetal bovine serum (FBS), 20 mM Hepes, 5 mM EDTA, and dithiothreitol (0.15 mg/ml) for 10 min with constant agitation by droppers in a 37C water bath. The digested cells that were collected were intraepithelial lymphocytes. Then, the left small intestine was incubated in a solution of 3% FBS, 20 mM Hepes, DNase I (0.125 mg/ml), and collagenase II (0.5 mg/ml) in 37C prewarmed DMEM for 5 min with constant agitation by droppers in a 37C water bath, and the dissociated cells that were collected were LP lymphocytes. Last, the collected cells were isolated by passing the tissue through a 200-mesh cell filter membrane, followed by 80%/40% Percoll (GE Healthcare) gradient centrifugation. Cells were carefully removed from the interface, washed with PBS, and resuspended in culture medium for further analysis.

All flow cytometric data were collected on a FACS Calibur or FACS LSR II system (both from BD Biosciences) and analyzed using FlowJo analysis software v7.6.1. For intracellular cytokine staining, cells were stimulated for 5 hours at 37C with phorbol 12-myristate 13-acetate (50 ng/ml; Sigma), ionomycin (1 mg/ml; Sigma-Aldrich), and brefeldin A (eBioscience). After staining for surface markers, cells were fixed and permeabilized according to the manufacturers instructions (eBioscience). Intracellular staining was processed using intracellular fixation buffer (eBioscience), and a TF staining buffer set (eBioscience) was used for RORt and Foxp3 staining. For the detection of phosphorylated STAT3 by flow cytometry, BD Phosflow Fix Buffer I and Perm/Wash Buffer I were used.

The following antibodies (clone names are in parentheses) with different fluorochrome labels were purchased from eBioscience: CD4 (RM4-5), CD8a (53-6.7), TCR (H57-597), CD44 (IM7), CD62L (MEL-14), IFN- (XMG1.2), IL-17A (TC11-18H10.1), IL-4 (11B11), and RORt (B2D). The following reagents were purchased from BioLegend: IL-23R (12B2B64), IL-21R (4A9), CD126 (D7715A7), Foxp3 (MF-14), and IL-17F (9D3.1C8).

For Western blot and ChIP, anti-Cxxc1 (1:1000 dilution for Western blot; 6 g for each immunoprecipitation and ChIP reaction; ab56035) was purchased from Abcam. H3K4me3 (4 g for each ChIP reaction; 39915) was purchased from Active Motif. AntipC-SMAD2 (3101), anti-SMAD2 (3103), anti-SMAD3 (9523), antipC-SMAD3 (9520), anti-STAT3 (Tyr705) (9131), anti-STAT3 (9132), anti-Erk (Thr202/Tyr204) (4370), anti-Erk (4695), anti-JNK (T183/Y185) (9251), and anti-JNK (9258) were obtained from Cell Signaling Technology.

Naive CD4+ T cells (CD4+CD25CD62LhiCD44lo) were purified by a FACS Aria II flow cytometer or sorted by the Mouse CD4 Nave T cell Enrichment Kit (no. 8804-6824-74, Invitrogen). Naive CD4+T cells were cultured with irradiated (30 Gy) anaphase-promoting complex sorted from spleen at a ratio of 1:3 and were activated with anti-CD3 (2 g/ml) and anti-CD28 (3 g/ml) in a 48-well plate (5 105 T cells per well). T cells were cultured in RPMI 1640 medium supplemented with 10% FBS, sodium pyruvate, penicillin-streptomycin, and 2-mercaptoethanol.

For nonpathogenic TH17 cell differentiation, culture medium was supplemented with IL-6 (20 ng/ml), TGF-1 (5 ng/ml), antiIL-4 (10 ng/ml), antiIL-12 (10 ng/ml), and antiIFN- (10 ng/ml). For pathogenic TH17 cells differentiation, culture medium was supplemented with IL-1 (20 ng/ml), IL-6 (20 ng/ml), and IL-23 (20 ng/ml), antiIL-4 (10 ng/ml), antiIL-12 (10 ng/ml), and antiIFN- (10 ng/ml). Other T cell differentiation were performed: TH1, IL-12 (20 ng/ml) and antiIL-4 (10 mg/ml); TH2, IL-4 (50 ng/ml), antiIFN- (10 ng/ml), and antiIL-12 (10 mg/ml); iTreg cells, TGF-1 (5 ng/ml), antiIL-4 (10 ng/ml), antiIL-12 (10 ng/ml), and antiIFN- (10 ng/ml). Neutralizing antiIFN- (XMG1.2), antiIL-4 (11B11), and antiIL-12 (C17.8) were from BioLegend.

Retroviruses were produced in Plat-E cells. Plat-E cells were transfected with pMX-IRES-GFP plasmids containing the indicated genes, and the medium was replaced twice with 3 ml of fresh medium every 10 hours after transfection. The retrovirus-containing supernatant was collected 72 hours after the medium was replaced for the second time and used to infect T cells.

Sorted naive CD4+ T cells were differentiated into TH17 cells in the presence of TGF-1 and IL-6 (48-well plate, 0.5 106 cells per well); 20 to 24 hours later, the cells were transfected with 1 ml of the indicated retrovirus in the presence of polybrene (10 g/ml) and 10 mM Hepes and infected for 2 hours at 1500g at 32C. After transfection, the cells were resuspended in TH17 differentiation medium and cultured for 3 days. The indicated cytokines (e.g., IL-17A and IL-17F) and other TFs (e.g., Foxp3 and RORt) were measured by gated CD4+GFP+ cells after retrovirus infection for 72 hours.

For RNA-seq, total RNA was extracted from naive CD4+ T cells differentiated in the presence of TGF-1 (5 ng/ml) and IL-6 (20 ng/ml) for 24 or 72 hours using the RNeasy kit (Qiagen). Library construction and sequencing were performed on a BGISEQ-500 platform by the Wuhan Genomic Institution (www.genomics.org.cn; BGI, Shenzhen, China). All reads were mapped to the mm10 mouse genome, and the uniquely mapped reads were subjected to RNA-seq data analysis using the Hierarchical Indexing for Spliced Alignment of Transcripts system (40).

ChIP assays were performed according to the manufacturers instructions with modifications using the ChIP-IT kit (Active Motif, USA). Briefly, the TH17 cells were fixed with 1% formaldehyde, and then, the cross-linked chromatin was sonicated in a 4C water bath using a Bioruptor Pico sonicator (Diagenode) to obtain DNA fragments between 150 and 500 base pairs (bp) in size. For Cxxc1 ChIP-seq, 5 106 TH17 of cells and 6 g of Cxxc1 antibody were used for each sample. For H3K4me3 ChIP-seq, 3 106 of TH17 cells and 4 g of H3K4me3 antibody were used for each sample.

The immunoprecipitated DNA was purified and subjected to sequencing library preparation using a VAHTSTM Universal DNA Library Prep Kit for Illumina V2 (Vazyme Biotech Co. Ltd.) according to the manufacturers protocol. The DNA libraries were then sequenced with an Illumina HiSeq X Ten system at Veritas Genetics in Hangzhou.

Sequenced reads of 150 bp were obtained using the CASAVA 1.8.2 package (Illumina). All reads were mapped to the mm10 mouse genome, and uniquely mapped reads were subjected to a further peak identification process. MACS2_V2.1.1 was used to identify significant peaks (q = 0.05) with both input DNA and ChIP DNA in Cxxc1-deficient cells as controls. The output of the peak files was converted by IGV browser. To calculate the tag density for Cxxc1-binding sites or H3K4me3 modifications around the TSS or at the centers of CGIs, uniquely mapped tags were summarized in 100-bp windows, and all window tag counts were normalized by the total number of bases in the windows and the total read number for the given sample.

Statistical analyses were performed using GraphPad Prism (GraphPad Software). The statistical significance was determined by Students t test. All error bars shown in this article represent SDs. Significance levels (P values) are presented in the figures.

Acknowledgments: We thank X. L. Liu (Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences) for gifts of cell lines; J. Qiu (Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences) for providing C. rodentium and mice; L. Shen (Zhejiang University) for helping with ChIP-seq data analysis; H. Y. Fang (Zhejiang University) for providing reagents; and L. R. Lu and D. Wang for their helpful discussion. We thank Y. Y. Huang, Y. W. Li, and J. J. Wang (Zhejiang University) for helping with the cell sorting; Y. Zhang and R. Ma (Zhejiang University) for feeding the mice. Funding: This work was supported, in part, by grants from the National Basic Research Program of China 973 Program (2015CB943301), the National Natural Science Foundation of China (81830006, 31670887, 31870874, and 31800734), Zhejiang Provincial Key Project of Research and Development (2019C03043), the Zhejiang Natural Science Foundation (LQ16H030003), and the Zhejiang Science and Technology Program(2017C37117 and 2017C37170). Author contributions: L.Wa. and F.L. designed the research. F.L., X.M., Y.G., W.C., Q.X., Z.H., W.L., J.C., S.H., and X.Z. performed the experiments and data analysis. L.Wa. and F.L. wrote the manuscript. L.L., C.W., J.W., W.Q., L.We., and D.W. provided expertise and advice. L.We. and L.Wa. supervised the project. Competing interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Data and materials availability: All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. The ChIP-seq and RNA-seq datasets were deposited in the GSE accession:GSE132208 and the SRA accession: PRJNA545626. Additional data related to this paper may be requested from the authors.

Excerpt from:
Epigenetic initiation of the TH17 differentiation program is promoted by Cxxc finger protein 1 - Science Advances

Interview with Tamer Mohamed of Aspect Biosystems on Advancing Tissue Therapeutics – 3DPrint.com

While attending The University of British Columbia (UBC), Tamer Mohamed, along with fellow graduate student Simon Beyer, began working at the Walus Laboratory on the development of a novel microfluidics-based bioprinting platform that could be used to fabricate human tissue constructs. One of the main reasons for their innovation was to potentially replace animal models in drug testing, which are costly, time-consuming and can have poor predictive accuracy. A few years went by and the two went on to win a MEMSCAP Design Award for their pioneering creation (the Lab-on-a-Printer Bioprinter) which would later become the basis for their startup, Aspect Biosystems. The UBC spinoff company was founded by Mohamed, Beyer, Konrad Walus (associate professor at UBC and head of the Walus Lab), and Sam Wadsworth, to turn their idea into a commercial product. The company quickly began providing pharmaceutical companies with high-efficacy tissue models that better mimicin vivoconditions, looking to improve the predictive accuracy of the front end drug discovery process. 3DPrint.com spoke to Mohamed to learn about his successful transition from graduate student to CEO of Aspect Biosystems.

Cofounders of Aspect Biosystems Tamer Mohamed and Simon Beyer at the Walus Lab when they were grad students

What was the inspiration behind Aspect Biosystems?

Aspect Biosystems was established with the vision of leveraging advancements in biology, microfluidics, and 3D printing to create technology-enabled therapeutics that will ultimately have a meaningful impact on patients. We are marrying our deep knowledge of human biology with cutting-edge 3D printing technology to create. Our story started almost a decade ago so weve spent years developing our foundational microfluidic bioprinting technology and are now applying our platform technology to create functional tissues, both internally through our proprietary programs, and with our partners around the world.

Can you tell me about the companys growth model?

Platform technologies often have the advantage of flexibility, as they could allow you to pursue multiple applications. This also presents a challenge though, in that it is easy to become unfocused. At Aspect, weve built a strategy that allows us to both focus and diversify. Internally, we are advancing proprietary tissue programs in regenerative medicine. But we also recognize that to achieve our vision of enabling human tissues on demand, we cant work alone. By providing access to our technology to partners around the world, we are able to create a network effect and tap into specific domain expertise. This allows our technology to be applied to a wide range of research purposes externally, without detracting resources or focus from our specific tissue programs internally. We collaborate with academia and industry on specific applications that allow us to fuel our growth and help generate revenue and a robust innovation pipeline.

How much has Aspect grown?

Aspect is the first and only company to leverage microfluidics to create functional tissue, and we are proud to pioneer this approach. Academically, we were one of the first groups in the world to print cells while at the UBC, so we see ourselves as pioneers in both bioprinting and platforms for creating tissue therapeutics. Five years ago, we had four full-time employees. Today we have a team of over 40 people focused on our mission and over 20 collaborations globally. We have attracted smart venture capital, partnered with some of the biggest names in our industry, and made major breakthroughs in applying our technology to create functional tissues. It is a great sign that, year-after-year, we continue to raise the bar. It is an even better sign that I believe the best is yet to come.

The Aspect Biosystem team celebrating Canada Day

What will the applications of this technology be in pharmaceutical research and drug trials?

I believe the opportunity with the highest value and best poised to make a significant impact on the pharmaceutical space is disease modeling. Using 3D bioprinting technology allows us to model diseases in a human-relevant system that would otherwise be difficult to study in animals or less sophisticated in vitro models. For example, working with GSK and Merck, we are leveraging our microfluidic 3D bioprinting platform to create physiologically-relevant 3D tissues containing patient-derived cells to assess the efficacy of anti-cancer drugs and to predict a patients response to treatment. This partnered program could unlock the discovery of novel therapeutic targets and the development of immuno-oncology therapeutics.

Would you tell us more about Aspects current and future work?

Our current internal programs are focused on orthopedic and metabolic diseases. On the orthopedic side, we are leveraging our deep knowledge of musculoskeletal biology and biomaterials to create knee meniscal replacements. On the metabolic side, we are focused on liver tissue and creating a therapeutic tissue for Type 1 diabetes. Externally, our partners around the world are using our 3D bioprinting technology to advance research in the brain, lungs, heart, pancreas, and kidneys, just to name a few. By being both focused internally and diversified externally, we are building a robust pipeline for the future. Our end goal is to enable the creation of human tissues on demand, and we know that we cant do it alone. Our network of academic researchers and industry partners are key to making our vision a reality.

How fast is the technology moving towards a future with lab-made functional organs?

Tamer Mohamed

We are focused on identifying specific diseases or biological malfunction inside the body and rationally designing advanced tissue therapeutics that address these areas of unmet medical need. So, while we may not actually be making something that looks exactly like an organ, we are recreating the biological function that has been lost or damaged to address the problem. For example, someone with Type 1 diabetes has a pancreas that is unable to perform the vital function of creating insulin. We dont necessarily need to engineer something for them that looks exactly like a pancreas instead, we are creating an implantable therapeutic tissue that replaces function that has been lost. In this case, that function is sensing glucose levels in the blood and biologically releasing insulin in response. This is an example of one of our internal programs a bioengineered pancreatic tissue therapeutic that restores a critical function that been lost due to an autoimmune disease.

Is Canada a great place to develop a bioprinting company?

Canada has a long and rich history in the field of regenerative medicine, going back to the discovery of stem cells in the 1960s. As a country, we have an opportunity to be a global leader in the field. At Aspect, we are proud to be part of these efforts. We are in ongoing discussions with different government groups as to how we can play a role in helping to lead the charge and the government has been embracing that. We have seen significant federal and provincial support for innovation and public/private partnerships, which definitely help stimulate growth in the field.

How disruptive is the technology you created?

By combining microfluidics with 3D printing, we are disrupting tissue engineering. We are able to programmatically process multiple cells and biologically-relevant materials in high-throughput to rationally design and produce functional tissues. We are constantly integrating new microfluidic processing units within our printhead technology and leveraging continuous advancements in the lab-on-a-chip space. With our microfluidic technology, we are generating a large amount of data. By using this data and machine learning, we are improving the quality and automation of the biomanufacturing process.

Ultimately, bioprinting is only as good as our understanding of biology and our understanding of biology is growing wider and deeper. We are combining state-of-the-art stem cell science with our microfluidic 3D printing technology to create tissue therapeutics. For example, we are combining insulin-secreting cells derived from human embryonic stem cells (hESCs) with our printing technology to create therapeutic tissues for patients with Type 1 diabetes.

Read more:
Interview with Tamer Mohamed of Aspect Biosystems on Advancing Tissue Therapeutics - 3DPrint.com